Get the Stockscreener App
5.51
1.81%
-0.1013
After Hours:
5.57
0.06
+1.09%
Jaguar Health Inc stock is traded at $5.51, with a volume of 10,340.
It is down -1.81% in the last 24 hours and down -53.01% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$5.6113
Open:
$5.46
24h Volume:
10,340
Relative Volume:
0.30
Market Cap:
$3.42M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.3404
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+7.62%
1M Performance:
-53.01%
6M Performance:
-82.08%
1Y Performance:
-97.77%
1-Day Range:
$5.2967
$5.62
1-Week Range:
$4.89
$6.125
52-Week Range:
$4.02
$540.00
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
5.51 | 3.42M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus
First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan
Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance
Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus
Jaguar Health to discuss breast cancer treatment with FDA - Investing.com
Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan
Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split - ACCESS Newswire
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com
Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire
Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
Jaguar Animal Health Secures $3.448M in Private Placement - TipRanks
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials - ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health Expands Workforce: New Stock Grants Signal Growth Strategy - Stock Titan
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) - ACCESS Newswire
Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN
Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa
Jaguar Health completes $3.4 million private placement - Investing.com India
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Jaguar Health Advances Plant-Based Pharmaceuticals - TipRanks
Jaguar Health’s Earnings Call: Growth Amid Challenges - TipRanks
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 - Investing.com Canada
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline By Investing.com - Investing.com South Africa
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline - Investing.com Australia
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 By Investing.com - Investing.com South Africa
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 - ACCESS Newswire
Jaguar Health, Inc. SEC 10-K Report - TradingView
StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX) - Defense World
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey - Weatherford Democrat
Jaguar Health at Emerging Growth Virtual Conference: Strategic Catalysts Ahead - Investing.com
Jaguar Health CEO, board members and investors invest in $3.448M bridge financing - MSN
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study - ACCESS Newswire
Mytesi Shows Promising Results in Breast Cancer: FDA to Review Game-Changing Phase 3 Data - Stock Titan
Jaguar Health secures $3.448 million in convertible notes By Investing.com - Investing.com South Africa
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):